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Common multi-allelic copy-number variants (CNVs) appear enriched for phenotypic 
associations compared to their di-allelic counterparts
1-5
. Here we investigated the 
influence of gene-dosage effects on adiposity through a CNV association study of 
gene expression levels in adipose tissue. We identified significant association of a 
multi-allelic CNV encompassing the salivary amylase gene (AMY1) with body mass 
index and obesity, and replicated this finding in 6,200 subjects. Increased AMY1 
copy-number was positively associated with both amylase gene expression 
(P=2.31×10
-14
) and serum enzyme levels (P<2.20×10
-16
), while reduced AMY1 copy-
number was associated with increased BMI (per-estimated-copy:β=-
0.15[0.02]kg/m²;P=6.93×10
-10
) and obesity risk (per-estimated-copy:OR=1.19[1.13-
1.26]95%CI;P=1.46×10
-10
). The OR of 1.19 per-copy of AMY1 translates to about an 
eight-fold difference in risk of obesity between subjects in the top (CN>9) and bottom 
(CN<4) 10% of the copy-number distribution. Our study provides a first genetic link 
between carbohydrate metabolism and BMI and demonstrates the power of integrated 
genomic approaches beyond genome-wide association studies. 
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We designed a gene-centric association study (GCAS) to identify common CNVs 
overlapping genes and inducing a dosage effect on gene expression, hypothesising 
that these might be enriched for physiologically-relevant CNVs. To achieve this, we 
conducted a family-based association analysis of signal intensity data from DNA 
arrays (log R ratio and B-allele frequency) using transcriptomic data from adipose 
tissue using famCNV
6
 in 149 Swedish families ascertained through siblings 
discordant for obesity (Table 1;Figure 1;Supplementary Figure 1). A total of 76 
probes located within putative CNVs showed a dosage effect on gene expression at 
1% FDR (Supplementary Table 1). Of these probes, only cnvi0020639, located 
within a CNV overlapping the amylase gene cluster (including the AMY1 salivary and 
the AMY2 pancreatic genes expression probeset 208498_s_at; FDR=6.88×10
-3
), was 
also associated with adiposity [both BMI (P=3.86×10
-4
) and fat mass (P=3.11×10
-4
)] 
(Supplementary Figures 2-4). Reduced signal intensity at this probe was associated 
with increased adiposity levels (Table 2;Figure 2;Supplementary Figures 2-4). 
 
This inverse association between copy-number in the amylase region and BMI was 
first replicated using signal intensity data from DNA arrays in 972 subjects from 
TwinsUK (Table 1)
7. The strongest association was observed at cnvi0022844 
(P=1.13×10
-3
;Table 2), which showed significant association with BMI after 
Bonferroni correction. When multiple probes were considered through principal 
component analysis, the BMI association signal actually extended over a region 
between cnvi0022844 and cnvi0016754 (P=1.32×10
-3
), which overlapped the 
cnvi0020639 probe associated with adiposity in the Swedish discovery families. 
These results, although supportive of the association in the amylase region, did not 
permit us to distinguish which of the salivary or pancreatic amylases was driving the 
5 
 
association with adiposity, necessitating use of a non-array-based method of copy-
number measurement. 
 
Consequently, we estimated copy-number at AMY1 and AMY2 in 481 subjects from 
the Swedish families (Table 1) using quantitative real-time PCR (qPCR). This 
approach generates a continuous intensity distribution from which integer copy-
numbers can be inferred by comparison to a reference sample of known copy-number 
(Supplementary Information). Given the many technical challenges inherent in 
copy-number measurement at multi-allelic loci
2,5,8-10
, we treated these discretised 
measurements as relative estimates or surrogates correlated with the true underlying 
copy-number state, as opposed to absolute copy-number genotypes.   
 
Only three estimated copy-number states (one to three) were detected for the 
pancreatic amylase (AMY2) gene, and these were not associated with either BMI or 
fat mass (Supplementary Table 2). In contrast, copy-number estimates at AMY1 
ranged from two to fourteen, and showed association with both BMI (P=8.08×10
-3
) 
and fat mass (P=8.53×10
-3
) confirming our previous DNA-array based analysis 
(Supplementary Table 2). We found greater correlation between signal intensity at 
cnvi0020639 and AMY1 (r=0.73; P<2.20×10
-16
) than AMY2 copy-number (r=0.35; 
P=1.25×10
-8
), suggesting that the GCAS association was mainly capturing copy-
number variation at AMY1 as opposed to AMY2, justifying follow-up of the former. 
Furthermore, we validated accuracy of the AMY1 qPCR assay by using whole-
genome shotgun-sequencing data from the 1000 Genomes Project, and observed a 
correlation of 0.94 (P<2.20×10
-16
) between AMY1 copy-number estimates derived by 
qPCR and sequencing (Supplementary Figures 5-8; Supplementary Table 3). To 
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further validate the AMY1 qPCR assay, we also compared the copy-number measured 
by qPCR in 96 samples from the DESIR cohort with AMY1 copy-number measured 
by digital PCR in the same samples, obtaining high correlation between the two 
methods (r=0.95; P<2.20×10
-16
; Supplementary Figure 9). Analogously, high 
correlation (r=0.98%; P<2.20×10
-16
; Supplementary Figure 9) was also observed 
between copy-numbers measured using our qPCR assay and those obtained using a 
different qPCR assay on the same 96 DESIR samples. 
 
To replicate the observed association in a larger sample, we next estimated AMY1 
copy-number by qPCR in an additional sample of 1,479 female subjects from 
TwinsUK and 2,137 male and female subjects from DESIR (Table 1). The two 
population samples showed a similar copy-number distribution (Wilcoxon test 
P>0.05) with estimated median copy-number of six, ranging from one to eighteen 
(Supplementary Figure 10; Supplementary Tables 4-5). Meta-analysis of AMY1 
effects in TwinsUK and DESIR (total n=3,616) showed significant association 
between AMY1 and BMI (per copy-number β=-0.15[0.02]kg/m²;P=6.93×10-10; Table 
2;Figure 3;Supplementary Tables 6-9). Results of associations assessed using both 
the qPCR intensity signal as a continuous measure, as well as discretised using an 
unsupervised clustering approach (k-means), were concordant with those generated 
using integer copy-numbers (Supplementary Information). 
 
We then assessed the effect of AMY1 copy-number on obesity susceptibility by 
selecting obese cases (BMI≥30kg/m2) and normal-weight controls (BMI<25kg/m2) 
from TwinsUK and DESIR and by measuring AMY1 copy-number by qPCR in an 
additional 205 severely obese cases and 358 age-matched controls from the AOB
11
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study (Table 1;Supplementary Information). In these European samples, subjects 
with lower estimated AMY1 copy-number showed significantly increased risk of 
obesity in each of the three samples (per-estimated AMY1 copy-number meta-
analysis: OR=1.19[1.13-1.26]95%CI;P=1.46×10
-10
;Table 2;Figure 3). The AMY1 copy 
number distribution in our sample ranged from one to eighteen copies, with 
approximately 10% of subjects carrying fewer than four copies of AMY1, and 10% of 
subjects with an AMY1 copy number greater than nine (Table 2). Given the multi-
allelic nature of the AMY1 CNV, this OR of 1.19 per copy of AMY1 translates to 
about an eight-fold difference in risk of obesity between subjects in the top (CN>9) 
and bottom (CN<4) decile of the estimated AMY1 copy-number distribution 
(OR=7.67[3.92-14.99]95%CI;P=2.52×10
-9
;Supplementary Table 10).  Using a multi-
factorial liability threshold model
12
, we estimated the proportion of total variance of 
obesity explained by estimated AMY1 copy-number to lie between 1.73-
7.94%[95%CI] (Supplementary Table 11). Therefore, based on an estimated 
heritability of 40-70%
13,14
, copy-number variation at AMY1 may account for 2.47-
19.86% of the total genetic variation of obesity. Analogously, we estimated that 
between 0.66% and 4.40% of the proportion of genetic variance of BMI could be 
explained by inferred AMY1 copy-number in these European samples.  
 
As all the samples included in our analyses were of European origin, we reasoned that 
replication in a sample of different ethnicity and under differing environmental 
influences on obesity would provide greater support for its physiological role. We 
therefore selected a Singaporean Chinese case-control sample from SP2
15
. A total of 
136 obese and 197 overweight subjects were identified among the 2,431 Chinese 
subjects included in the SP2 cohort, with 325 matched lean Chinese SP2 normal-
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weight controls. AMY1 copy-number was measured by qPCR in all 658 subjects. 
Median copy-number in SP2 normal-weight subjects was 6 (ranging from 2 to 16), 
similar to our French DESIR and UK populations, and in line with previous 
observations by Perry et al
16
. Case-control association analysis in the Chinese sample 
showed reduced AMY1 estimated copy number to be associated with increased risk of 
obesity (per copy-number OR=1.17[1.05-1.29]95%CI;P=3.73×10
-3
). Extending the case 
sample to include milder overweight subjects further confirmed the results (per copy-
number OR=1.13[1.06-1.21]95%CI;P=3.52×10
-4
).  
 
To validate our AMY1 genomic copy-number data at the protein level, we investigated 
the effect of copy-number variation at AMY1 and AMY2 on serum amylase enzyme 
levels, and their relationship with BMI using 468 French morbidly obese subjects 
from the ABOS study (Table 1;Supplementary Table 12). On average, salivary and 
pancreatic amylase proportions were approximately equal in serum (52% and 48%, 
respectively) and their levels showed close positive association with copy-number 
variation at their respective genes (P<2.20×10
-16 
and P=1.04×10
-11
, respectively; 
Supplementary Figure 11). BMI was inversely associated with salivary amylase 
(β=-0.23[0.04]kg/m²;P=2.26×10-7;Supplementary Figure 12) and to a lesser extent 
pancreatic amylase (β=-0.23[0.06]kg/m²;P=2.29×10-4;Supplementary Figure 12), 
likely reflecting the physiological correlation between the levels of the two enzymes 
(r=0.21;P=4.29×10
-6
).  
 
Salivary amylase catalyses hydrolysis of theα -1,4-glycosidic bonds of starch, 
initiating carbohydrate digestion in the oral cavity. While individual salivary amylase 
levels vary in response to environmental factors including psychological stress
17
, they 
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are genetically influenced by and directly correlated with the highly variable copy-
number at AMY1
16,18
. Increased gene copy-numbers at this locus are believed to have 
evolved in the human lineage as a consequence of a shift to a starch-rich diet
19
. 
Human populations traditionally consuming a high proportion of carbohydrates in 
their diet show higher copy-numbers and salivary amylase activity than those 
consuming a low-starch diet
16,20
. Both the salivary glands and pancreas contribute 
similarly to determine overall levels of serum amylase
21
, although enzyme activity is 
also detectable in other organs, including adipose tissue
22,23
. Indeed amylase was 
among the 30% most-highly expressed genes in adipose tissue in both our discovery 
sample and publicly-available data from the general population, thus suggesting that 
this gene is actively expressed in adipose tissue (Supplementary Information). 
Whether adipose tissue is functionally involved in the link between AMY1 copy-
number and obesity, or whether this link implicates a different tissue in which AMY1 
is also actively transcribed warrants further investigation. 
 
Decreased blood amylase levels have been observed in both obese humans
24
 and 
rats
25
, and have recently been associated with increased risk of metabolic 
abnormalities
26,27
 and reduced pre-absorptive insulin release
28
. Furthermore, a recent 
study in mice fed a high fat/high sugar diet suggested association between the 
amylase locus and weight gain
29
. In these mice, this locus was also shown to be 
associated with the proportion of Enterobacteriaceae in murine gut microbiota
29
, 
previously correlated with obesity in humans
30
.  
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Rare copy-number variants have recently been implicated in highly-penetrant forms 
of obesity
31,32
 and severe thinness
33
, through a gene dosage effect. Common biallelic 
CNVs have also been associated with BMI
34-37
, however, since most of these are 
reliably tagged by surrounding SNPs
38
,
 
they share the same properties of small effect 
sizes and limited predictive value for obesity risk. In contrast, complex multi-allelic 
CNVs show decreased linkage disequilibrium with surrounding SNPs 
(Supplementary Table 13) and are consequently less detectable by SNP-based 
GWAS
39
. Surprisingly, FTO is the most-replicated obesity susceptibility gene 
identified through GWAS
37
, yet in our analyses the estimated AMY1 copy-number 
appeared to show stronger association with BMI than FTO SNPs (Supplementary 
Tables 14-15). It is conceivable that high structural variability in the amylase region 
and subsequent low SNP coverage (Supplementary Figures 13-14) may have 
hampered previous SNP-based GWAS attempts to detect association between the 
amylase cluster and adiposity. Indeed, examination of data from the most recent BMI 
meta-analysis conducted by the GIANT consortium
37
 revealed a large gap in SNP 
coverage across the locus encompassing the salivary amylase genes (Supplementary 
Figure 14).  
 
Present DNA high-throughput methods for CNV assessment, including array-, PCR- 
and sequencing-based approaches, are all affected by a wide number of variables 
including DNA source, extraction methods, quality and concentration, as well as 
experimental factors inducing batch effects
9,10,40
. These factors complicate copy-
number measurement at multi-allelic CNVs and hinder pooling of data from multiple 
centres.  
11 
 
The observed association of AMY1 with obesity may rekindle interest in the role of 
multi-allelic CNVs in common disease, driving development of novel technological 
approaches for accurate and high-throughput measurement of absolute copy-number 
at such loci. These technological improvements will enable high-quality association 
analyses at such loci in larger sample sizes similar to those included in SNP 
association studies, and are mandatory for disease risk-assessment at the individual 
level, paving the way towards personalized medicine. 
 
Our study provides a first genetic link between carbohydrate metabolism and obesity, 
with low copy-number at AMY1 resulting in decreased salivary amylase levels and a 
higher risk of obesity. This finding provides intriguing insight into some of the 
biological mechanisms underlying obesity, as well as a novel rationale for the 
investigation of innovative obesity treatments based on manipulation of digestive 
enzyme levels.  
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ONLINE METHODS 
Further detailed methods are provided in the Supplementary Information.  
Associations were assessed using linear mixed effects models, including plate as a 
random effect and family structure as an additional random effect where appropriate. 
Age and sex were included as covariates.  
Discovery. The discovery sample included 149 Swedish families (342 subjects) 
ascertained through an obesity-discordant sib-pair (BMI difference>10kg/m
2
)
41
. Gene 
expression for 29,546 transcripts (16,563 ENSEMBL genes) was measured in 
subcutaneous adipose tissue using the Affymetrix Human Genome U133 Plus 2.0 
microarray. GWAS signal intensity data from Illumina 610K-Quad arrays were 
available for 348,150 probes lying within each transcript plus 30kb upstream and 
downstream to encompass the coding regions and their internal and nearby regulatory 
regions.  
Quantitative real-time PCR (qPCR) was carried out to infer relative copy-number 
measurements reflecting the underlying copy-number distribution at AMY1 and 
AMY2, respectively, using the TaqMan assays Hs07226362_cn and Hs04204136_cn 
on an Applied Biosystems 7900HT Real-Time PCR System. Association analyses 
were carried out for 481 subjects with complete data on BMI and dual-energy X-ray 
absorptiometry (DEXA)-derived fat mass. 
Replication. In-silico replication of the BMI association was conducted using 972 
female subjects from the UK adult twin registry (TwinsUK) cohort
42
 using intensity 
signals from Illumina 610K-Quad arrays
7
. Association with BMI and obesity was 
analysed in two population samples using qPCR estimates of AMY1 copy-number for 
1,479 female twins from TwinsUK and 2,137 subjects from the French Data from the 
Epidemiological Study on the Insulin Resistance syndrome (DESIR)
43
 cohort. Obesity 
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association with qPCR data was also assessed in an additional case-control sample of 
205 obese cases and 358 age-matched controls from the French Adult Obesity study 
(AOB)11. An additional case-control sample was extracted from the Singapore 
Prospective Study Program (SP2) cohort, a population-based study including 2,431 
adult Chinese Singaporean subjects
15
. Cut-offs were defined by the Working Group 
on Obesity in China
44
and the WHO expert consultation for Asia
45
, which define 
obesity in the Chinese population as BMI≥28kg/m2 and normal-weight as 
BMI<23kg/m
2
. Obesity in the Chinese population was thus defined as BMI ≥ 28kg/m2 
and normal-weight as BMI < 23kg/m
2
. Accordingly, a total of 136 obese and 197 
overweight subjects were identified among the 2,431 Chinese subjects of the SP2 
cohort, with 325 matched lean SP2 subjects selected as normal-weight controls. 
In order to avoid any potential population stratification impacting on our association 
analyses resulting from the known differences in AMY1 copy number distribution 
between populations traditionally consuming high versus low starch diets
16
, we 
carried out genotype principal component analysis using genome-wide SNP array 
data to ensure that samples included in each analysis were of the same ethnicity and 
genetic background. Furthermore, AMY1 association analyses were conducted 
separately in each of the study populations and then combined by meta-analysis using 
METAL
46
 rather than pooling.  
Protein levels. ‘Atlas Biologique de l’Obésité Sévère’ (ABOS) is a French cohort 
comprised of candidates for bariatric surgery. Serum pancreatic and salivary amylase 
levels for 468 patients were measured by an enzymatic colorimetric assay with an 
autoanalyzer (CoBAS Icobas® 8000 modular analyser series; kits AMYL2-
03183742122 and AMY-P-20766623322, Hoffman-La Roche Ltd). 
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Figure Legends 
 
Figure 1: Manhattan plot of gene-centric CNV association study (GCAS) association 
results with gene expression levels in subcutaneous adipose tissue from the Swedish sib-
pair dataset. Chromosomal location for each probe is given on the horizontal axis for each of 
the 22 autosomes, while minus log10 (P) of the association between probe signal intensity and 
gene expression levels is shown on the vertical axis. The probes tested against the amylase 
genes transcriptional levels are shown in green. 
 
Figure 2: The amylase region in detail. Top to bottom: famCNV association results 
between probe signal intensity at probes within 30kb of the amylase cluster and amylase 
expression levels (probeset 208498_s_at) in adipose tissue (black dots) in the Swedish family 
discovery study, with chromosomal coordinates given on the horizontal axis and minus 
log10(P) on the vertical axis; locations of associated probes: cnvi0020639 (blue; Swedish 
family discovery study), cnvi0022844 (red; TwinsUK); gene content in the amylase region 
based on the human reference sequence (hg19; RefSeq), depicting AMY2B, AMY2A and the 
AMY1A/B/C genes, as well as two high sequence similarity segmental duplications in the 
region; LD between HapMap markers (release 23) calculated with HaploView
46 
(darker 
shading corresponds to higher r
2
 value). Because of the repetitive nature of this region, which 
contains six paralogs (including one pseudogenized copy) in the reference genome 
(Supplementary Figure 13), the cnvi0020639 and the cnvi0022844 probes were found to 
map to two locations within the amylase gene cluster. 
 
Figure 3. Effect of estimated AMY1 copy-number on obesity and BMI. A: Scatter plots of 
raw qPCR signal intensity (ΔΔCt) plotted against BMI for the TwinsUK and DESIR samples. 
B: Boxplots of ΔΔCt in normal weight (BMI<25kg/m2) and obese (BMI≥30kg/m2) subjects in 
the TwinsUK, DESIR and AOB samples. For plots A and B, low ΔΔCt values correspond to 
high AMY1 copy-numbers. C: relative copy-number distribution in obese cases (BMI≥30 
kg/m
2
; black bars) versus normal weight controls (BMI<25 kg/m
2
; grey bars) in the 
TwinsUK, DESIR, and AOB studies. Estimated copy-numbers higher than 13 (showing 
frequency < 2.5%) were collapsed together into a single category. D and E: BMI at different 
estimated AMY1 copy-numbers and AMY1 copy-number estimates by BMI categories in the 
TwinsUK and DESIR population samples. WHO BMI classification: Underweight (<18.5); 
Normal range (18.50 – 24.99); Pre obese (25.00 – 29.99); Obese class I (30.00 – 34.99); 
Obese class II (35.00 – 39.99). Error bars represent the standard error of the mean. 
*Association between BMI and qPCR ΔΔCt intensity signal, corrected for age, sex (DESIR), 
family (TwinsUK) and genotyping plate. **Wilcoxon rank sum test. 
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Tables 
 
Table 1: Summary information on subjects included in this study. 
 
 
*Consisting of 334 dizygotic and 193 monozygotic twin pairs and 425 singletons.  **Including 136 obese (BMI ≥ 
28 kg/m2) and 197 overweight (28 kg/m2 > BMI > 23 kg/m2) Singaporean Chinese subjects. 
 
 
 
 
 
  
Sample    Total Male Female 
Median 
age 
1
st
 – 3rd 
quartiles 
Median 
BMI  
1
st
 – 3rd 
quartiles 
Swedish        342 98 244 37 (33 - 43) 27.9 (22.6 - 36.5) 
TwinsUK 1,479* - 1,479 53 (45 - 60) 26.0 (22.8 - 28.4) 
DESIR     2,137 942 1,195 52 (44 - 61) 24.6 (22.2 - 26.6) 
AOB        563 160 403 35 (32 - 39)          - - 
    Cases        205 39 166 36 (29 - 41) 46.2 (42.5 - 51.3) 
    Controls        358 121 237 35 (33 - 38) 21.6 (20.3 - 22.4) 
SP2        658 237 421 46 (37 - 52)          - - 
    Cases
**
        333 139 194 47 (40 - 54) 27.1 (25.9 - 28.9) 
    Controls        325 98 227 44 (34 - 51) 18.4 (17.5 - 19.1) 
ABOS        468 122 346 43 (33 - 51) 46.2 (41.7 - 52.3) 
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Table 2: Association of relative copy-number in the amylase region with obesity and measures of adiposity. Copy-number estimates used in the association 
analyses for both the "Population samples" and the "Obesity case-control" samples were derived by qPCR.   
 
DNA Array-based 
CNV analysis# 
N Trait Associated probe   P   
Swedish families 342 BMI cnvi0020639    3.86×10-4   
Swedish families 331 Fat mass cnvi0020639    3.11×10-4   
TwinsUK 972 BMI cnvi0022844    1.13×10-3   
         
Population samples ‡ N BMI*  Age* β (SE)§ P    
TwinsUK 1,479 26.0 (22.8-28.4)  53 (45-60) -0.18 (0.05) 5.91×10-4   
DESIR 2,137 24.6 (22.2-26.6)  52 (44-61) -0.14 (0.03) 2.49×10-7   
         
 N    β (SE) § P   Het P** 
Meta analysis 3,616    -0.15 (0.02) 6.93×10-10  0.54 
         
 Cases                    Controls      
Obesity case-control‡ N Age* N Age* β (SE) § P OR (95%CI) §  
TwinsUK 251 53 (47-60) 711 51 (44-59) -0.26 (0.09) 3.61×10-3 1.30 (1.08-1.55)  
DESIR 137 55 (47-64) 1267 51 (42-59) -0.16 (0.04) 7.47×10-5 1.18 (1.09-1.27)  
AOB 205 36 (29-41) 358 35 (33-38) -0.17 (0.04) 4.44×10-5 1.19 (1.10-1.29)  
SP2 136 47 (37-54) 325 44 (34-51) -0.15 (0.05) 3.73×10-3 1.17 (1.05-1.29)  
 N  N  β (SE) § P OR (95%CI) § Het P** 
Meta analysis*** 593  2,336  -0.18 (0.03) 1.46×10-10 1.19(1.13-1.26) 0.62 
 
The listed numbers of samples are those which passed quality control and were used in the association analyses. ‡ Obesity case-control analyses in TwinsUK and DESIR were 
conducted using a subset (subjects with BMI < 25kg/m2 and those with BMI ≥  30kg/m2) of those subjects included in the quantitative trait analysis in the population samples 
category. #“DNA Array-based” denotes signal intensity data from Illumina SNP genotyping arrays; * median (1st, 3rd quartiles) ; ** Heterogeneity P-value;  §  Estimates calculated 
using integer AMY1 copy-numbers inferred from the underlying continuous distribution. ***Obesity case-control meta-analysis was limited to European samples. 
 
 
